In line with our findings, it has been recently reported that SRC signaling mediates acquired resistance to ALK inhibitors and dasatinib sensitizes ALK-rearranged NSCLC to ALK inhibitors [33]. This evidence concerns the gene ALK and non-small cell lung carcinoma.